Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Pfizer Beats On Profits Through Aggressive Cost Cutting
- Mike Havrilla submits: click to enlarge Pfizer PFE posted an EPS of $0.62 on revenues of just under $12B, which was two cents ahead of consensus earnings estimates and in-line with revenue estimates for the quarter. The company raised its full-year revenue view to $48-$49B while narrowing its earnings estimate to...
- External links 2008-10-21
- Earnings Encore for Amgen?
- Mike Havrilla submits: click to enlarge by Mike Havrilla
- External links 2008-10-22
- Commodity Fund That Tracks Global Coal Price
- Mike Havrilla submits: The accompanying table click to enlarge contains a summary and statistics for 16 ETFI global equity indexes and two commodity pool fund ideas, with the short/inverse and defensive themes outpacing the overall market averages over the past year in the midst of ongoing market turmoil around the...
- External links 2008-10-26
- Biogen Reports Another Tysabri Glitsch
- Mike Havrilla submits: click to enlarge After the market close, Biogen BIIB filed an 8-K with the SEC reporting a new case of the potentially fatal brain disease known as PML or progressive multifocal leukoencephalopathy in a patient receiving their multiple sclerosis [MS] drug Tysabri, adding to the two new...
- External links 2008-10-30
- BioSante: Key Support Is Back
- Mike Havrilla submits: Earlier this week BioSante Pharma BPAX reported 3Q08 results which included a net loss of $6.6M or ($0.24) per share and a loss of $16.3M or ($0.60) per share for the first nine months of the year. The primary focus at the company is the development of...
- External links 2008-11-14
- Achillion Pharma: Hepatitis Drug Dev Pipeline Now Fully Funded
- Mike Havrilla submits: Achillion Pharma ACHN is a promising micro-cap biotech, specializing in the development of new treatments for infectious diseases, such as the multi-billion dollar market for the chronic treatment of hepatitis C. As I recently wrote, several companies in this space have been bought out at huge premiums...
- External links 2008-11-25
- Caraco Pharma Is a Compelling Value at This Price
- Mike Havrilla submits: Caraco Pharma CPD offers a compelling value at its current price of $3.30 per share and I bought some shares today, as the stock has lost an astounding two-thirds of its market value in just the past month and over three-quarters of value in the past year.1.)...
- External links 2008-12-02
- China Medical Embraces Molecular Diagnostics
- Mike Havrilla submits: China Medical CMED offers a compelling value since losing about 60% of its market value in the past year, with shares trading very close to August 2005 IPO levels at the close yesterday of under 18 bucks click on chart to enlarge. CMED is also included in...
- External links 2008-12-25
- Trading FDA Decisions: AMAG Looks Like a Buy
- Mike Havrilla submits: With shares of AMAG Pharma AMAG declining by about 11% in the past five days and after listening to the conference call from late December again, I am adding to my long position in the company on the potential for FDA approval of Feraheme ferumoxytol during 1Q09....
- External links 2009-01-09
- Caraco Pharma Awaits FDA Inspection in May
- Mike Havrilla submits: I spoke with the investor relations representative for Caraco Pharma CPD earlier this week and received some clarity on the expected timeline for resolving the major overhang on the stock price related to the FDA warning letter over Form 483 concerns by the agency stemming from quality...
- External links 2009-02-25
- Updated Clinical Trial Notes on Somaxon, Theravance
- Mike Havrilla submits: 1.) Somaxon SOMX Silenor doxepin NDA - Filed under 505b Pathway - New Indication for an Approved, Generically Available Drug. Somaxon's new formulation of doxepin is at lower doses (1, 3, 6 mg) compared to existing generic products on the market at doses of 10mg-150mg to reduce...
- External links 2009-03-01
- More Than a Few Reasons to Buy CombiMatrix
- Mike Havrilla submits: CombiMatrix CBMX is an ETF Innovators Emerging Diagnostics Index component and spin-off company from Acacia Research ACTG, which has operated independently since August 2007 as a developer of DNA MicroArrays for lab-based personalized medicine applications to improve treatment outcomes, which are exempt from the more time-consuming and...
- External links 2009-03-13
- Javelin Pharma's Late-Stage Pipeline Pain
- Mike Havrilla submits: Javelin Pharma JAV is focused on the late stage clinical development of three Phase 3 compounds while seeking partnerships for a non-dilutive source of funding. In mid-January, JAV established a partnership for Dyloject injectable diclofenac with Therabel Pharma to market the drug in Europe, where it is...
- External links 2009-03-16
- King Pharma: Value Play on New Drug Approvals
- Mike Havrilla submits: King Pharma KG is a specialty pharmaceutical company which recently acquired Alpharma for $1.6B and has three pending NDAs at the FDA for new drug approvals and received a complete response late last year for Remoxy (an abuse deterrent form of extended-release oxycodone) along with Pain Therapeutics...
- External links 2009-03-20
- Summary of Electro-Optical Sciences' Corporate Presentation
- Mike Havrilla submits: Since I last wrote about Electro-Optical Sciences MELA positive results for MelaFind as a new diagnostic screening device for melanoma, the Company presented at the Cowen and Company Healthcare conference. Below is a summary of the presentation, including the razor/razor blade business model and targeted commercialization plans...
- External links 2009-03-24
- Rockwell Medical Technologies: Improving Margins, Banking on SFP
- Mike Havrilla submits: In mid-March, Rockwell Medical Technologies RMTI reported 4Q and FY08 results which included revenue of $13.5M (up 13.3% from year-ago quarter) and $51.6M (up 20% compared to 2007). The net losses were ($3M) and ($7.9M) for 4Q and FY08, respectively. Despite solid sales growth, RMTI has posted...
- External links 2009-03-26
- CareView Communications Could Outperform
- Mike Havrilla submits: The ETF Innovators Health IT Index has been a strong performer over the past month, with many of the major components outpacing the 6% gain in the S&P 500 ETF SPY during that period. The following are some top performing stocks which have posted double digit stock...
- External links 2009-03-26
- NeurogesX Awaiting Dual Regulatory Decisions
- Mike Havrilla submits: NeurogesX (NASDAQ:NGSX) represents a two-in-one extreme trade on pending FDA and EMEA regulatory decisions to market its nerve pain patch in both the E.U. and U.S. markets. NGSX was not included in my previous article of nine remaining extreme trades on pending FDA decisions since the Company...
- External links 2009-05-10
- FDA, Clinical Trial Calendar Updates: AMAG Pharma, Immunomedics
- Mike Havrilla submits: Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision...
- External links 2009-05-12
- NeoStem: Expanding Beyond Stem Cell Banking
- Mike Havrilla submits: NeoStem (AMEX:NBS) is a pioneer and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell...
- External links 2009-05-18
- << Previous
- page 1 of 3
- Next >>
